TARGIT: A Randomised Controlled Trial to Compare Targeted Intra-operative Radiotherapy With Conventional Post-operative Radiotherapy After Conservative Breast Surgery for Women With Early Stage Breast Cancer
TARGIT is an international randomised clinical trial designed to test the hypothesis that
the strategy of delivering a single dose of targeted intraoperative radiotherapy (IORT) in
patients eligible for breast conserving therapy (with the addition of whole breast
radiotherapy in those patients at high risk of recurrence elsewhere in the breast [e.g.
lobular carcinomas and extensive intraductal component]) is equivalent to a conventional
course of post-operative external beam radiotherapy (EBRT). The primary endpoints are local
and loco-regional recurrence rates. It is a pragmatic trial in which each participating
centre has the option to define more restrictive entry criteria than in the core protocol.
Only centres with access to the Intrabeam® (Carl Zeiss) enter patients into the trial.
Eligible patients are those with tumours of good prognosis suitable for breast conserving
surgery. After giving consent patients are randomised to either IORT or to EBRT. They may
receive any other adjuvant treatments as deemed necessary, except for neoadjuvant therapy.
The protocol requires that patients be followed at six monthly intervals for five years and
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Local relapse within the treated breast.
3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 108, 120 months
Jeffrey S Tobias, MD FRCP FRCR
University College London Hospitals
United Kingdom: Research Ethics Committee